Search
Tezacaftor
go.drugbank.com/drugs/DB11712ApprovedInvestigational[L1595] It was developed by Vertex Pharmaceuticals and FDA approved in combination with [ivacaftor] to manage cystic fibrosis.[L6814] This drug was approved by the FDA on February 12, 2018. … [L4894] Cystic Fibrosis is an autosomal recessive disorder caused by one of several different mutations in the gene for the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) protein, an ion
Pentobarbital
go.drugbank.com/drugs/DB00312ApprovedVet approvedIt is prescribed more frequently for sleep induction than for sedation but, like similar agents, may lose its effectiveness by the second week of continued administration. … A short-acting barbiturate that is effective as a sedative and hypnotic (but not as an anti-anxiety) agent and is usually given orally.
Products: Nova Rectal Sup 50mg, Nembutal Sodium Inj 50mg/mlLubiprostone
go.drugbank.com/drugs/DB01046ApprovedInvestigationalLubiprostone is a medication used in the management of idiopathic chronic constipation. A prostaglandin E1 derivative, lubiprostone is a bicyclic fatty acid that activates ClC-2 chloride channels located on the apical side of the gastroi...
Perampanel
go.drugbank.com/drugs/DB08883ApprovedInvestigationalPerampanel is a noncompetitive AMPA glutamate receptor antagonist. It is marketed under the name Fycompa™ and is indicated as an adjunct in patients over 12 years old for the treatment of partial-onset seizures that may or may not occur ...
Products: FYCOMPA FILM-COATED TABLET 10MG, Fycompa 10mg Film-coated TabletsMethacholine
go.drugbank.com/drugs/DB06709Approved[A229648, L31763] Methacholine was granted FDA approval on October 31, 1986, and is marketed under the trademark PROVOCHOLINE® by Methapharm Inc.[L31763] … [A229598, A229603] Although the underlying pathology of AHR is complex, ASM contraction can be stimulated by cholinergic agonists that activate M<sub>3</sub> muscarinic receptors that stimulate ASM contraction
Cryptenamine
go.drugbank.com/drugs/DB00785ApprovedIt has been used in the treatment of hypertension but has largely been replaced by drugs with fewer adverse effects.
Tedizolid
go.drugbank.com/drugs/DB14569ApprovedInvestigational[L11232, A199086, A199050] Tedizolid was approved by the FDA on June 20, 2014, for sale by Cubist Pharmaceuticals as tedizolid phosphate (SIVEXTRO®).
Fidanacogene elaparvovec
go.drugbank.com/drugs/DB16783ApprovedInvestigational[L49469,L46691] Fidanacogene elaparvovec was also approved by the FDA on April 26, 2024.[L50577] … [L46691] Hemophilia B is a rare X-linked genetic disorder characterized by abnormal coagulation due to dysfunctional coagulation factor IX with a male incidence estimated to be 1 in 30,000 male births
Mavorixafor
go.drugbank.com/drugs/DB05501ApprovedInvestigationalby a reduced number of mature neutrophils and lymphocytes. … [L50647] WHIM syndrome is caused by mutations in the _CXCR4_ gene, which leads to overactivation of CXCR4 signalling pathways.[A263652] Mavorixafor prevents the activation of CXCR4.
Famotidine
go.drugbank.com/drugs/DB00927ApprovedInvestigationalFamotidine is a competitive histamine-2 (H2) receptor antagonist that works to inhibit gastric acid secretion. It is commonly used in gastrointestinal conditions related to acid secretion, such as gastric ulcers and gastroesophageal refl...
Mixtures: ETOFAM 400MG/20MG FİLM KAPLI TABLET, 20 ADET, ETOPLUS 400MG/8MG/20MG FİLM KAPLI TABLET, 14 ADETProducts: GASTRUM 20MG, Pepcid Tab 20mg